Anti-FASL monoclonal antibody, clone HN6G5

We aimed to evaluate the association of Fas polymorphism and the Fas ligand with preeclampsia, investigating whether the G 670 Fas gene variant and the Fas Ligand INV2nt 124 G variant had a differential distribution in patients with preeclampsia. The preeclamptic group consisted of 50 pregnant women who developed preeclampsia, while the control group consisted of 50 age-matched pregnant women with uncomplicated pregnancies. Fas and Fas ligand gene polymorphisms were tested using polymerase chain reaction-restriction fragment length polymorphism. Regarding the Fas 670 A > G polymorphism, statistically significant differences were found between the two groups regarding the AA and GG/AG genotypes as well as the A, G allele frequency, while no statistically significant differences were found regarding AG or GG genotypes. Regarding the FasLG IVS2nt 124 A > G polymorphism, no statistically significant differences were found between the two groups studied. Concerning the Fas 670 A > G gene, no statistically significant differences between the severe and mild preeclampsia groups regarding the A allele frequency were found. Concerning the FasLG IVS2nt 124 A > G gene, there were no statistically significant differences between the severe and mild preeclampsia groups regarding the A allele frequency or the G allele frequency. The presence of the Fas gene polymorphism Fas A670G is associated with an increased risk of preeclampsia, while the presence of FasLG IVS2nt 124 A > G gene may be protective against preeclampsia. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

Background: FAS and FASLG together initiate apoptosis, which prevents tumor development. FAS and FASLG polymorphisms in the promoter regions can alter the transcriptional activities and thus alter risk of cancer. We hypothesized that the FAS - 1377G > A, - 670A > G, and FASLG -844T > C polymorphisms are associated with risk of bladder cancer. Methods: In a hospital-based case-control study of 216 case patients with newly diagnosed bladder transitional cell carcinoma and 252 cancer-free controls frequency-matched by age and sex, we genotyped polymorphisms using PCR-restriction fragment length polymorphism. Results: We found a statistically significantly increased risk of bladder cancer associated with the FASLG - 844CC genotype [adjusted OR = 1.51; 95% CI 1.03-2.23] compared with - 844 (CT + TT). Consistently, the FAS haplotype genotypes with 2-4 variant (risk) alleles (-1377A and -670A) were associated with an increased risk of bladder cancer compared to 0-1 variants (OR = 2.14; 95% CI 1.10-4.16). Furthermore, when we evaluated these three polymorphisms together, we found that the combined genotypes with 4-6 variant (risk) alleles (-1377A, -670A, and -844C) were associated with an increased risk of bladder cancer (OR = 1.58; 95% CI 1.07-2.34) compared to 1-3 variants, and this increased risk was more pronounced among subgroups of aged > 50 years (OR = 1.70; 95% CI 1.11-2.61) and smokers (OR = 1.88; 95% CI 1.06-3.32). Conclusions: FAS and FASLG polymorphisms appear to jointly contribute to risk of bladder cancer in this southern Chinese population. Larger studies are needed to verify these findings.